Analysis of Fas (Apo-1/CD95) Expression in Non-small Cell Lung Cancer

Vincenzo Esposito, Alfonso Baldi, Giuseppina Liuzzi, Giuseppe Tonini, Bruno Vincenzi, Paolo Persichetti, Mario Santini, Vincenzo Ambrogi, Tommaso Claudio Mineo, Vincenzo Montesarchio, Ernst Wolner, Feliciano Baldi, Angela M. Groeger

Research output: Contribution to journalArticlepeer-review


Defects in the apoptotic pathway represent a critical element in the progression of neoplastic disease and may also concur to determine treatment efficacy at the cellular level. Fas (Apo-1/CD95) is a cell-surface receptor involved in cell death signaling. In this study we analyzed, by immunohistochemistry, the expression of Fas protein in a group of 68 NSCLC (non-small cell lung cancer) specimens. Statistical analyses did not show any significant relationship between Fas immunohistochemical expression and clinical parameters of lung cancer patients, except for nodal status. Our data do not support the use of Fas as a molecular prognostic role in NSCLC. On the other hand, considering the role of the Fas-pathway in chemotherapy-induced apoptosis, further studies are required to analyze the potential value of Fas expression in predicting the response of NSCLC patients to chemotherapy.

Original languageEnglish
Pages (from-to)4901-4905
Number of pages5
JournalAnticancer Research
Issue number6 C
Publication statusPublished - Nov 2003


  • Fas
  • Immunohistochemistry
  • Non-small cell lung cancer
  • Survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'Analysis of Fas (Apo-1/CD95) Expression in Non-small Cell Lung Cancer'. Together they form a unique fingerprint.

Cite this